Publications by authors named "Manuela J Regenbrecht"
Article Synopsis
- Cell culture models are essential for cancer research, but TET cells are particularly challenging to grow due to limited available permanent cell lines.
- Current knowledge about the optimal conditions for culturing different TET subtypes is lacking, which may hinder progress in understanding their biology and therapy options.
- While alternative methods like organoid models and patient-derived xenografts have been used, more research is needed to validate their effectiveness for studying TETs.
Functional Precision Medicine Successfully Guides Therapeutic Regimen of 'Cancer of Unknown Primary' Later Classified as Triple-Negative Breast Cancer: A Case Report.
Larissa Ruhe Sonja Heibl Manfred Czompo Johannes Haybaeck Jürgen Loskutov Manuela Johanna Regenbrecht Christian René Alexander Regenbrecht
Case Rep Oncol
March 2024
Introduction: Controlled randomized trials, molecular analytics, and guideline recommendations have so far been irreplaceable tools to ensure appropriate treatment and decision-making for physicians and patients. Individual patient models are increasingly complementing these methods, particularly in the case of advanced cancers, rare cancers, and cancers of unknown primary (CUP), as in these cases comprehensive clinical evidence is unavailable, often resulting in poor treatment success, even after stratification.
Case Presentation: Here we report a 53-year-old patient with CUP with axillary lymph node metastases for whom patient-derived 3D (PD3D) tumor organoids successfully guided personalized treatment.